Search research articles
Contact Us
Filters
Showing results (71-80 of 76) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
M S van der Heijden, T Powles, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 76) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 76 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
ESMO Open
|
August 12, 2025
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
M S van der Heijden, T Powles, S Gupta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V Conteduca, D Wetterskog, M T A Sharabiani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 20, 2019
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†
A Horwich, M Babjuk, J Bellmunt, et al.
Page
of 8